Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer

Table 2 Diagnostic performance

	AUC	95% CI	Sensitivity	Specificity	PPV	NPV	Accuracy
MUC5AC
PC vs. controls	0.825	0.760–0.890	0.541	0.951	0.846	0.807	0.815
EPC vs. controls	0.793	0.695–0.890	0.500	0.951	0.714	0.886	0.863
LPC vs. controls	0.856	0.783–0.930	0.581	0.951	0.75	0.900	0.877
CA19-9
PC vs. controls	0.836	0.770–0.902	0.820	0.618	0.515	0.874	0.685
EPC vs. controls	0.844	0.752–0.937	0.833	0.618	0.347	0.938	0.660
LPC vs. controls	0.827	0.740–0.914	0.806	0.618	0.347	0.927	0.656
Combination
PC vs. controls	0.894	0.844–0.943	0.738	0.886	0.763	0.872	0.837
EPC vs. controls	0.892	0.819–0.966	0.767	0.886	0.622	0.940	0.863
LPC vs. controls	0.895	0.837–0.954	0.710	0.886	0.611	0.924	0.851

AUC area under receiver operating characteristic curve, EPC early-stage pancreatic cancer, LPC late-stage pancreatic cancer, NPV negative predictive value, PC pancreatic cancer, PPV positive predictive value

ISSN: 1477-7819